Monoclonal antibodies derived from B cells in subjects with cystic fibrosis reduce
Malika Hale, Kennidy K Takehara, Christopher D Thouvenel, Dina A Moustafa, Andrea Repele, Mary F Fontana, Jason Netland, Sharon McNamara, Ronald L Gibson, Joanna B Goldberg and 2 more
Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Kennidy K Takehara *Department of Immunology, University of Washington School of Medicine, Seattle, United States.
Christopher D ThouvenelCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, United States.
Dina A MoustafaDivision of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Department of Pediatrics, Emory University School of Medicine, Atlanta, United States.
Andrea RepeleCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, United States.
Jason NetlandDepartment of Immunology, University of Washington School of Medicine, Seattle, United States.
Sharon McNamaraCystic Fibrosis Center, University of Washington/Seattle Children's Hospital, Seattle, United States.
Ronald L GibsonCystic Fibrosis Center, University of Washington/Seattle Children's Hospital, Seattle, United States.
Joanna B GoldbergDivision of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Department of Pediatrics, Emory University School of Medicine, Atlanta, United States.
University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4M
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4M
University of Washington Medical Scientist Training ProgramT32GM153182 · NIGMS · UNIVERSITY OF WASHINGTON · PI MARSHALL S. HORWITZ · 2024 to 2026
$5.3M
Cystic Fibrosis Foundation SINGH19R0NIDDK NIH HHS P30 DK089507NIGMS NIH HHS T32 GM007266NIGMS NIH HHS T32 GM153182NIH HHS 5T32GM007266NIH HHS P30DK089507Seattle Children's Foundation Tom Hansen Investigator for Pediatric Innovation Endowment
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Monoclonal antibodies derived from B cells in subjects with cystic fibrosis reduce · full record | OpenQuestion